A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants With Inflammation (High C-Reactive Protein)

November 16, 2026 updated by: Eli Lilly and Company

A Phase 1, Randomized, Participant- and Investigator-Blinded, Placebo Controlled, Single-Dose and Multiple-Ascending Dose Study of Orally Administered LY5625573 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Participants, Including Japanese and Chinese Populations, and in Participants With Elevated C-Reactive Protein

The purpose of this study is to learn if LY5625573 is safe and how well it is tolerated in healthy participants, including Japanese and Chinese participants, and in participants with high levels of a marker for inflammation (C-reactive protein). The study will also look at how the body absorbs, breaks down, and clears the study drug (pharmacokinetics), how the study drug works in the body, and whether it interacts with certain other medications by affecting how the body processes them.

Participation in the study will last up to approximately 7 weeks for Part A and 8.5 weeks for Parts B, C, D, and E. For each participant there will be one stay at the clinical research unit (CRU) lasting 5 nights for Part A, 18 nights for Parts B and C, and 17 nights for Parts D and E.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

96

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
  • Phone Number: 1-317-615-4559
  • Email: LillyTrials@Lilly.com

Study Contact Backup

Study Locations

      • Singapore, Singapore, 138623
        • Not yet recruiting
        • Lilly Centre for Clinical Pharmacology
        • Contact:
          • Phone Number: 64139811
        • Principal Investigator:
          • Jeffer Hann Wei Pang
    • California
      • Los Alamitos, California, United States, 90720
        • Not yet recruiting
        • Collaborative Neuroscience Network - CNS
        • Principal Investigator:
          • Steven Reynolds
    • Texas
      • Dallas, Texas, United States, 75247
        • Recruiting
        • Fortrea Clinical Research Unit
        • Principal Investigator:
          • Gene Voskuhl
        • Contact:
          • Phone Number: 866-429-3700

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 21 to 65 years of age, inclusive, at the time of signing the informed consent if enrolled in Singapore
  • Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and cardiac monitoring
  • Have clinical laboratory test results within normal reference range for the population or investigative site, or results with acceptable deviations that are judged to be not clinically significant by the investigator
  • Have a hemoglobin level of at least 12.5 grams per deciliter (g/dL) for participants assigned male at birth (AMAB) and at least 11.4 g/dL for participants assigned female at birth (AFAB)
  • Individuals AFAB who are individual not of childbearing potential (INOCBPs) may participate in this trial

Parts A, B, D, and E

  • Have a body mass index (BMI) greater than or equal to (≥)18.5 and less than or equal to (≤) 32.0 kilograms per square meter (kg/m²)
  • Have an estimated glomerular filtration rate (eGFR), using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation 2021, of ≥90 milliliter per minute per 1.73 square meters (mL)/minute/1.73 m² at screening

Part C

  • Have a BMI ≥18.5 and <40.0 kg/m²
  • high-sensitivity C-reactive protein (hsCRP) ≥2 milligrams per liter (mg/L) and ≤15 mg/L at screening and Day -2 (as confirmed by local laboratory).
  • Have an eGFR, using the CKD-EPI creatinine equation 2021, of ≥60 mL/minute/1.73 m² at screening

Part D

  • To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan

Part E

  • To qualify as Chinese for this study, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China

Exclusion Criteria:

  • History of active tuberculosis or presence of active or latent tuberculosis
  • History or evidence of clinically significant opportunistic infection
  • History of serious local infection (for example, cellulitis or abscess) or systemic infection within 90 days prior to screening
  • Have any nonserious but active infections
  • History of more than one episode of herpes zoster infection or history of disseminated herpes zoster infection
  • Have a 12-lead electrocardiogram (ECG) abnormality
  • Clinically significant abnormal laboratory test results at screening, or positive serology test results for hepatitis B surface antigen, hepatitis B core total antibody, hepatitis C virus antibody, or human immunodeficiency virus antigen and antibody, or QuantiFERON®-TB test at screening

Parts A, C, D, and E

  • History of significant allergic reactions to any medication or known allergic reactions to drugs related to LY5625573 (VTX3232) or to any excipient in the formulation of LY5625573

Part B

  • History of significant allergic reactions to any medication or known allergic reactions to drugs related to LY5625573 (VTX3232), midazolam, or to any excipient in the formulation of LY5625573 or midazolam

Parts B, C, D, and E

  • Have answered "yes" to either Question 4 or Question 5 on the "Suicidal Ideation" portion of the Columbia Suicide Severity Rating Scale (C-SSRS) and the ideation occurred within the past 90 days (at screening and/or Day -1 [Day 2 for Part B])
  • Have a baseline Patient Health Questionnaire-9 (PHQ-9) score of 15 or greater, and/or a score of 2 or greater for either of the first 2 questions on the PHQ-9 questionnaire (at Day -1[Day 2 for Part B]

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: LY5625573 Part A - Single Dose Healthy

Single dose of LY5625573 administered orally in healthy participants

Administered orally as tablet

Other Names:
  • VTX3232
Placebo Comparator: Placebo Part A - Single Dose Healthy

Single dose of Placebo administered orally in healthy participants

Administered orally as tablet

Experimental: LY5625573 + Midazolam Part B - Multiple Dose Healthy

Multiple-ascending dose (MAD) of LY5625573 and midazolam co-administered orally in healthy participants

Administered orally

Administered orally as tablet

Other Names:
  • VTX3232
Placebo Comparator: Placebo + Midazolam Part B - Multiple Dose Healthy

Multiple doses of Placebo and midazolam co-administered orally in healthy participants

Administered orally

Administered orally as tablet

Experimental: LY5625573 Part C - Multiple Dose Elevated hsCRP

MAD of LY5625573 administered orally in participants with elevated high-sensitivity C-reactive protein (hsCRP)

Administered orally as tablet

Other Names:
  • VTX3232
Placebo Comparator: Placebo Part C - Multiple Dose Elevated hsCRP

Multiple doses of Placebo administered orally in participants with elevated hsCRP

Administered orally as tablet

Experimental: LY5625573 Part D - Healthy Japanese

MAD of LY5625573 administered orally in healthy Japanese participants

Administered orally as tablet

Other Names:
  • VTX3232
Placebo Comparator: Placebo Part D - Healthy Japanese

Multiple doses of Placebo administered orally in healthy Japanese participants

Administered orally as tablet

Experimental: LY5625573 Part E - Healthy Chinese

MAD of LY5625573 administered orally in healthy Chinese participants

Administered orally as tablet

Other Names:
  • VTX3232
Placebo Comparator: Placebo Part E - Healthy Chinese

Multiple doses of Placebo administered orally in healthy Chinese participants

Administered orally as tablet

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Time Frame: Baseline up to Follow up (Days 12 and 24)
Baseline up to Follow up (Days 12 and 24)
Number of Participants with One or More Treatment-Emergent Adverse Event(s) (TEAEs) Considered by the Investigator to be Related to Study Drug Administration
Time Frame: Baseline up to Follow up (Days 12 and 24)
Baseline up to Follow up (Days 12 and 24)

Secondary Outcome Measures

Outcome Measure
Time Frame
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY5625573
Time Frame: Baseline up to End of Treatment (Day 17)
Baseline up to End of Treatment (Day 17)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 29, 2026

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

January 1, 2027

Study Registration Dates

First Submitted

October 5, 2026

First Submitted That Met QC Criteria

October 5, 2026

First Posted (Actual)

October 9, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 27937
  • J7V-MC-EOBB (Other Identifier: Eli Lilly and Company)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.